Trial reportEuropean journal of nutrition2025
Curcumin plus piperine improve body composition in patients with inflammatory bowel disease: a randomized, double-blind, placebo-controlled clinical trial.
Trial report in European journal of nutrition, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
3 citing papers in PubMed.
- Curcumin for inflammatory bowel disease therapy: advances in mechanisms, clinical applications, and drug delivery.Archives of pharmacal research · 2025Review
- Curcumin in Inflammatory Complications: Therapeutic Applications and Clinical Evidence.International journal of molecular sciences · 2025Review
- Curcumin: a potential anti-photoaging agent.Frontiers in pharmacology · 2025Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
12 authors.
Funding
Abstract
This study evaluates the effects of oral supplementation of curcumin alone and curcumin plus piperine on body composition, phase angle, and functional capacity in patients with mild to moderate inflammatory bowel disease (IBD). Patients with a diagnosis of IBD, aged 18 years or older with intact kidney and liver function, were into three groups: placebo, curcumin (1000 mg/day), and curcumin plus piperine (1000 mg/day + 10 mg/day). Anthropometric markers, body composition, phase angle (via tetrapolar bioelectrical impedance analysis), and hand-grip strength were assessed before and after the 12-week supplementation period. Statistical analyses included Chi-square test (χ²) and generalized estimating equation (GEE) adjusted for age. Of the 58 patients who started the study, 51 completed it. Initially, obesity was prevalent according to BMI (43.1%) and body fat percentage (62.7%), while 86.3% exhibited muscle depletion based on fat-free mass (FFM). Post-intervention, the curcumin plus piperine group showed a significant reduction in muscle depletion, with improvements in FFM (χ², p = 0.019; GEE, p = 0.049) and phase angle (χ², p = 0.028) compared to the placebo group. In conclusion, our findings indicate that curcumin plus piperine significantly improves body composition by increasing muscle mass in patients with mild to moderate IBD, suggesting its potential as an adjuvant therapy. Trial registration: This trial was registered at ensaiosclinicos.gov.br as RBR89q4ydz on July 20, 2023. Website https://ensaiosclinicos.gov.br/ .
Indexed as
Identifiers
39934549What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.